Dafna Capital Management LLC Apellis Pharmaceuticals, Inc. Transaction History

Dafna Capital Management LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $1.2 Million - $1.72 Million	-25,700 Reduced 30.8%	57,746 $3.81 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $756,700 - $1.07 Million	17,500 Added 26.54%	83,446 $4.31 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $1.39 Million - $2.16 Million	-30,989 Reduced 31.97%	65,946 $4.5 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $105,210 - $177,630	3,000 Added 3.19%	96,935 $4.38 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $3.33 Million - $5.08 Million	93,935 New	93,935 $4.77 Million
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $398,874 - $887,177	-12,703 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$40.9 - $64.9 $1.32 Million - $2.09 Million	-32,223 Reduced 71.72%	12,703 $803,000
Q1 2021 May 17, 2021	BUY	$40.8 - $57.39 $41,208 - $57,963	1,010 Added 2.3%	44,926 $1.93 Million
Q4 2020 Feb 16, 2021	BUY	$30.79 - $57.2 $426,810 - $792,906	13,862 Added 46.12%	43,916 $2.51 Million
Q3 2020 Nov 16, 2020	SELL	$25.89 - $33.65 $90,615 - $117,775	-3,500 Reduced 10.43%	30,054 $907,000
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $508,400 - $789,045	-20,500 Reduced 37.93%	33,554 $1.1 Million
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $239,940 - $593,889	13,397 Added 32.95%	54,054 $1.45 Million
Q4 2019 Feb 14, 2020	SELL	$22.1 - $30.8 $2.85 Million - $3.98 Million	-129,143 Reduced 76.06%	40,657 $1.25 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $4.09 Million - $5.46 Million	169,800 New	169,800 $4.09 Million

310

113M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.29B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.